www.finanzen.net bietet Finanznachrichten zum weltweiten Boersengeschehenhttp://www.finanzen.netde-definanzen.net GmbHhttp://images.finanzen.net/images/finanzen_net_neu.gifhttp://www.finanzen.nethttp://www.finanzen.net/nachricht/Karo-Bio-Implements-Planned-Efficiency-Measures-1891880 Regulatory News: Karo Bio AB (publ) (STO:KARO) carries out the planned second phase of its efficiency program and reduces the number of employees by 10 to 44. The goal is for Karo Bio to become a company ...http://www.finanzen.net/nachricht/Karo-Bio-Implements-Planned-Efficiency-Measures-1891880http://www.finanzen.net/nachricht/Karo-Bio-Karo-Bio-s-Annual-Report-Now-Available-1879242 Regulatory News: Karo Bio AB (STO:KARO): Karo Bio AB’s annual report for 2011 is as of today available on the company’s website www.karobio.com. <!-- sh_cad_1 --> The printed version ...http://www.finanzen.net/nachricht/Karo-Bio-Karo-Bio-s-Annual-Report-Now-Available-1879242http://www.finanzen.net/nachricht/Notice-of-Annual-General-Meeting-of-Karo-Bio-AB-Publ-1859122 Regulatory News: The shareholders of Karo Bio AB (publ)(STO:KARO) are hereby given notice to attend the annual general meeting on June 12th, 2012, at 4.00 pm CET at H&ouml;rsalen, Novum Forskningspark (level ...http://www.finanzen.net/nachricht/Notice-of-Annual-General-Meeting-of-Karo-Bio-AB-Publ-1859122http://www.finanzen.net/nachricht/Extraordinary-General-Meeting-in-Karo-Bio-1825319 Regulatory News: Karo Bio AB (STO:KARO)(publ). At the Extraordinary General Meeting in Karo Bio the following resolutions were made. <!-- sh_cad_1 --> 1. The General Meeting resolved to approve the ...http://www.finanzen.net/nachricht/Extraordinary-General-Meeting-in-Karo-Bio-1825319http://www.finanzen.net/nachricht/Karo-Bio-Interim-Report-January-March-2012-1823961 <style type="text/css"> <!-- .bwlistitemmargb {margin-bottom: 10.0px} --> </style> Regulatory News: <!-- sh_cad_1 --> Karo Bio (STO:KARO) The January–March 2012 period in brief <!-- sh_cad_2 --> <ul> <li ...http://www.finanzen.net/nachricht/Karo-Bio-Interim-Report-January-March-2012-1823961http://www.finanzen.net/nachricht/Collaboration-with-Zydus-Cadila-Expires-Karo-Bio-Continues-to-Develop-Safer-Glucocorticoids-1770776 Regulatory News: Karo Bio AB (publ)(STO:KARO) and the Indian pharmaceutical company Zydus Cadila have decided not to further extend their joint glucocorticoid receptor research and development program. Karo ...http://www.finanzen.net/nachricht/Collaboration-with-Zydus-Cadila-Expires-Karo-Bio-Continues-to-Develop-Safer-Glucocorticoids-1770776http://www.finanzen.net/nachricht/Changed-Date-for-the-Annual-General-Meeting-and-Notice-to-Extraordinary-General-Meeting-of-Karo-Bio-1751636 Regulatory News: Karo Bio AB (publ).(STO:KARO): <!-- sh_cad_1 --> According to the previous press release of 14 February 2012, Karo Bio has discontinued the clinical phase III-project with the lipid-lowering ...http://www.finanzen.net/nachricht/Changed-Date-for-the-Annual-General-Meeting-and-Notice-to-Extraordinary-General-Meeting-of-Karo-Bio-1751636http://www.finanzen.net/nachricht/Karo-Bio-Lays-off-16-Employees-1668797 Regulatory News: Karo Bio AB (publ) (STO:KARO) completes notice of redundancy issued in November and lays off 16 employees. As previously announced, the purpose of this downsizing is to reduce costs. ...http://www.finanzen.net/nachricht/Karo-Bio-Lays-off-16-Employees-1668797http://www.finanzen.net/nachricht/Karo-Bio-Terminates-the-Eprotirome-Program-1649027 Regulatory News: Karo Bio AB (publ) has decided to discontinue the development program for eprotirome after an animal study has demonstrated unwanted effects following long-term exposure. The planned spin-off ...http://www.finanzen.net/nachricht/Karo-Bio-Terminates-the-Eprotirome-Program-1649027http://www.finanzen.net/nachricht/Karo-Bio-Information-regarding-trading-suspension-1646128 <style type="text/css"> <!-- .bwuline {text-decoration: underline} --> </style> Regulatory News: <!-- sh_cad_1 --> Karo Bio AB (publ)(STO:KARO) estimates to provide information on Tuesday morning related to the ...http://www.finanzen.net/nachricht/Karo-Bio-Information-regarding-trading-suspension-1646128